News
In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...
A potential $4 billion licensing deal with Vor Bio triggered a slide in RemeGen's stock price. Otsuka obtained a BCMAXCD3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback